Lyme disease vaccine set back by bodged Phase III trial

5 May 2023
lyme_disease_large

The poor execution of a Phase III trial in Lyme disease has set back plans to submit vaccine candidate VLA15 for regulatory approval in the USA.

Developers Valneva (Nasdaq: VALN) and Pfizer (NYSE: PFE) disclosed in February that they would have to  withdraw some participants from the VALOR study, after violations of clinical trial good practice were discovered.

The trial is being run by contract research organization (CRO) Care Access. In its quarterly results  statement, Valneva has now revealed that the setback will delay regulatory submissions until 2026.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology